Selecting initial treatment of acute myeloid leukaemia in older adults
- PMID:27745715
- DOI: 10.1016/j.blre.2016.09.005
Selecting initial treatment of acute myeloid leukaemia in older adults
Abstract
More than half of the patients with acute myeloid leukaemia (AML) are older than 60years. The treatment outcomes in this group remain poor with a median overall survival of <1year. Selecting initial treatment for these patients involves an assessment of 'fitness' for induction chemotherapy. This is done based on patient and disease-related characteristics which help to estimate treatment-related mortality and chance of complete remission with induction chemotherapy. If the risk of treatment-related mortality is high and/or the likelihood of a patient achieving a complete remission is low, lower-intensity treatment (low-dose cytarabine, decitabine and azacitidine) should be discussed. As outcomes in both groups of patients remain poor, enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with AML. Novel agents in Phase III development include CPX-351, guadecitabine (SGI-110), quizartinib, crenolanib, sapacitabine, vosaroxin and volasertib.
Keywords: AML; Clinical trial; Induction chemotherapy; Older adults; Treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.Kantarjian HM, et al.Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.Lancet Oncol. 2017.PMID:28844816Free PMC article.Clinical Trial.
- Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.Seymour JF, et al.BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.BMC Cancer. 2017.PMID:29241450Free PMC article.Clinical Trial.
- Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Ferrara F.Ferrara F.Hematol Oncol. 2014 Mar;32(1):1-9. doi: 10.1002/hon.2046. Epub 2013 Mar 20.Hematol Oncol. 2014.PMID:23512815Review.
- CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.Talati C, Lancet JE.Talati C, et al.Future Oncol. 2018 May;14(12):1147-1154. doi: 10.2217/fon-2017-0603. Epub 2018 Jan 30.Future Oncol. 2018.PMID:29378418Review.
- Acute myeloid leukemia in the elderly: therapeutic options and choice.Webster JA, Pratz KW.Webster JA, et al.Leuk Lymphoma. 2018 Feb;59(2):274-287. doi: 10.1080/10428194.2017.1330956. Epub 2017 Jun 2.Leuk Lymphoma. 2018.PMID:28573892Free PMC article.Review.
Cited by
- MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).Khurana A, Shafer DA.Khurana A, et al.Onco Targets Ther. 2019 Apr 16;12:2903-2910. doi: 10.2147/OTT.S172315. eCollection 2019.Onco Targets Ther. 2019.PMID:31289443Free PMC article.Review.
- Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.Kubasch AS, Platzbecker U.Kubasch AS, et al.Cancers (Basel). 2018 May 24;10(6):158. doi: 10.3390/cancers10060158.Cancers (Basel). 2018.PMID:29795051Free PMC article.Review.
- Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness.Palmieri R, Paterno G, De Bellis E, Mercante L, Buzzatti E, Esposito F, Del Principe MI, Maurillo L, Buccisano F, Venditti A.Palmieri R, et al.Cancers (Basel). 2020 Jan 2;12(1):120. doi: 10.3390/cancers12010120.Cancers (Basel). 2020.PMID:31906489Free PMC article.Review.
- Impact of Physicians' Personalities and Behavioral Traits on Treatment-Related Decision-making for Elderly Acute Myeloid Leukemia.Wu X, Jiang YN, Zhang YL, Chen J, Mao YY, Zhang L, Zhou DB, Cao XX, Li J.Wu X, et al.J Gen Intern Med. 2021 Oct;36(10):3023-3030. doi: 10.1007/s11606-020-06467-w. Epub 2021 Jan 28.J Gen Intern Med. 2021.PMID:33511569Free PMC article.
- Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation.Jung J, Lee H, Suh YG, Eom HS, Lee E.Jung J, et al.J Korean Med Sci. 2021 Mar 1;36(8):e55. doi: 10.3346/jkms.2021.36.e55.J Korean Med Sci. 2021.PMID:33650334Free PMC article.Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials